logo-loader

Full interview: Medexus Pharmaceuticals reveals 3Q highlights and potential acquisition activity

Published: 12:32 21 Feb 2020 EST

Medexus Pharmaceuticals Inc (CVE:KMDP) (OCTMKTS:PDDPF) CEO Ken d’Entremont tells Proactive the pharmaceutical company is showing strong organic growth from its three main revenue drivers, including Resuvo, Metoject, and Rupall, bringing revenue of C$16.2 million for its Q3, compared to revenue of C$14.4 million for the same period a year earlier.

d’Entremont says meanwhile, the company's expenses are growing - as strong evidence it has been 'very busy' on the business development front, expecting to potentially close an acquisition in the near future.

Medexus Pharmaceuticals reveals record quarterly revenue of C$31.5M

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQX:MEDXF) CEO Ken d’Entremont tells Proactive its fiscal third quarter results revealed record quarterly revenue of C$31.5M, nearly doubling its revenue year-over-year from C$16.2M in the same period in 2019. d’Entremont added given significant share...

on 2/3/21